VT300X

VT300X is a preclinical-stage therapeutic candidate being developed by Vigeo Therapeutics. According to the company's 2024 pipeline disclosures, the asset is characterized as a small molecule intended for the treatment of multiple undisclosed indications. Interestingly, earlier company documentation from 2021 categorized VT300X as a fusion molecule, which may indicate an evolution in the program's lead candidate or development strategy. As of early 2024, the specific biological targets and mechanism of action for VT300X remain proprietary and have not been publicly disclosed by the sponsor. Vigeo Therapeutics generally focuses on developing novel therapies that modulate the tumor microenvironment, particularly through the thrombospondin-1 (TSP-1) pathway, though it is not yet confirmed if VT300X utilizes this specific approach.